The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers
- 10 January 2013
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 40 (4), 363-370
- https://doi.org/10.1111/cup.12085
Abstract
Background Microcystic adnexal carcinoma (MAC), desmoplastic trichoepithelioma (DTE) and morpheaform basal cell carcinoma (BCC) frequently impose a considerable differential diagnostic challenge and immunohistochemistry is often used as a differentiating diagnostic adjunct. Methods Using standard immunohistochemical techniques, we examined 21 examples of DTE, 17 examples of morpheaform BCC and 10 examples of MAC for the expression of BerEP4, a marker of epithelial cells, and of three stem cell markers, pleckstrin homology‐like domain, family A, member 1 (PHLDA1) [T cell death‐associated gene 51 (TDAG51)], cytokeratin 15 (CK15) and cytokeratin (CK19). Results All but one MAC was negative for BerEP4 and all morpheaform BCC expressed BerEP4. Sixteen out of 21 DTE were immunoreactive for BerEP4. All 21 DTE were PHLDA1 positive and all 17 morpheaform BCC were PHLDA1 negative. MAC showed a mixed staining pattern for PHLDA1. CK15 was expressed in 20/21 DTE, whereas the majority of cases of MAC and morpheaform BCC were CK15 negative. CK19 stained more MAC than DTE and morpheaform BCC. Conclusions BerEP4 differentiates between MAC and morpheaform BCC but not between MAC and DTE whereas PHLDA1 differentiates between DTE and morpheaform BCC but shows variable staining in MAC. CK15 and CK19 are helpful adjuncts in the differential diagnosis of sclerosing adnexal neoplasms but are second in line to BerEP4 and PHLDA1. We propose an algorithm for the immunohistochemical work‐up of sclerosing adnexal neoplasms.Keywords
This publication has 24 references indexed in Scilit:
- Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin‐20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimensJournal of Cutaneous Pathology, 2011
- Stem cell markers can help identify adnexal tumor differentiation when evaluated in the context of morphology: methodology mattersJournal of Cutaneous Pathology, 2011
- p75 Neurotrophin receptor differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: insights into the histogenesis of adnexal tumours based on embryology and hair follicle biologyBritish Journal of Dermatology, 2010
- Markers to Evaluate the Quality and Self-Renewing Potential of Engineered Human Skin Substitutes In Vitro and after TransplantationJournal of Investigative Dermatology, 2009
- Immunohistochemistry in ocular carcinomasJournal of Cutaneous Pathology, 2008
- Microcystic adnexal carcinoma: an immunohistochemical reappraisalLaboratory Investigation, 2008
- Monoclonal antibody Ber‐EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinomaJournal of Cutaneous Pathology, 2007
- Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma?Journal of Cutaneous Pathology, 2007
- Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variantsJournal of Cutaneous Pathology, 2006
- Monoclonal Antibody Ber EP4 Distinguishes Basal-Cell Carcinoma from Squamous-Cell Carcinoma of the SkinThe American Journal of Dermatopathology, 1993